Predicting Outcomes With First-Line Antiangiogenics Plus Chemotherapy in mCRC

August 12, 2014
Paulo Marcelo Hoff, MD, PhD, FACP

Special Reports, Gastrointestinal Cancers (Issue 2), Volume 2, Issue 1

Paulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses predicting outcomes with first-line antiangiogenics plus chemotherapy in metastatic colorectal cancer (mCRC).

Paulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses predicting outcomes with first-line antiangiogenics plus chemotherapy in metastatic colorectal cancer (mCRC).

Learn about adverse events associated with regorafenib for mCRC > >